查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579433

雙胍類藥物市場：按類型、藥物類別、劑型、分銷管道分類 - 全球預測 2025-2030

Biguanides Market by Type (Finformin, Metformin), Drug Class (Branded, Generic), Dosage Form, Formulation, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年雙胍類藥物市場價值為52.4億美元，預計到2024年將達到55.1億美元，複合年成長率為5.37%，到2030年將達到75.7億美元。

雙胍類藥物主要應用於醫學領域，重點關注具有雙胍官能基的化合物，特別是Metformin，它是2型糖尿病的主要治療藥物。該市場的範圍超出了糖尿病治療，在體重管理和卵巢綜合症（PCOS）治療方面具有潛在的應用，並且這種需求已在各種治療領域得到證實。雙胍類藥物改善新陳代謝的特性正在促進其在製藥和醫療保健等最終用途領域的效用，同時由於其潛在的長壽作用，人們也在探索抗衰老療法。就市場洞察而言，主要成長要素包括全球糖尿病和METABOLIC INC.盛行率上升，刺激了對含雙胍藥物的需求。此外，增加對醫療基礎設施的投資以及藥物開發持續的技術創新也正在擴大市場。一個值得注意的商機是，健康意識的增強正在推動對更安全、長期的糖尿病管理的需求，另一個是雙胍類藥物作為腫瘤學輔助性治療的尚未開拓的潛力。然而，雙胍類藥物也存在一些潛在副作用，如乳酸性酸中毒，這需要謹慎的劑量和嚴格的監管障礙。此外，市場學名藥已飽和狀態，存在價格競爭壓力。創新的賭注應集中在製劑技術的進步上，這些技術可改善給藥機制並減少副作用，從而將雙胍藥物的範圍擴大到其傳統用途之外。此外，聯合治療的研究可以透過提高治療功效來提供競爭優勢。市場仍然充滿活力，監管變化和專利到期都會影響競爭策略。為了實現永續成長，公司應優先考慮策略夥伴關係，並利用資料分析來客製化以患者為中心的解決方案，以滿足新興需求。保持生物技術進步和醫療保健創新的領先地位將提高您在這個不斷變化的環境中的適應能力和市場滲透率。

主要市場統計
基準年[2023] 52.4億美元
預測年份 [2024] 55.1億美元
預測年份 [2030] 75.7億美元
複合年成長率（%） 5.37%

市場動態：揭示快速發展的雙胍類藥物市場的關鍵市場洞察

雙胍類藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 2 型糖尿病盛行率的增加增加了對雙胍類藥物等有效治療方案的需求
    • 增加醫療支出和政府努力提高糖尿病藥物的認知和可用性
    • 提高雙胍療效和患者依從性的配方技術進步
    • 越來越多的老年人口容易患糖尿病和相關併發症並需要標靶治療
  • 市場限制因素
    • 雙胍類藥物的潛在副作用限制了患者的依從性
    • 雙胍類藥物的研究、開發和商業化高成本
  • 市場機會
    • 雙胍類藥物研發進展聚焦新型遞送機制與劑型
    • 天然和植物來源雙胍在食品和食品中越來越受歡迎
    • 隨著醫療保健成本的增加和對文明病的認知的提高，新興市場的機會
  • 市場挑戰
    • 新替代品對醫藥應用中雙胍類需求的影響
    • 工業中長期使用雙胍類藥物所引起的環境與健康問題

波特五力：駕馭雙胍類藥物市場的策略工具

波特的五力框架是了解雙胍類藥物市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解雙胍類藥物市場的外部影響

外部宏觀環境因素對雙胍類藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解雙胍類藥物市場競爭狀況

雙胍類藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣雙胍類藥物市場供應商的績效評估

FPNV定位矩陣是評估雙胍類藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪雙胍類藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對雙胍類藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 2 型糖尿病盛行率的不斷上升增加了對雙胍類藥物等有效治療方案的需求。
      • 不斷上漲的醫療保健成本和政府努力提高糖尿病藥物的認知度和可用性
      • 藥物製劑技術的進步提高了雙胍類藥物的療效和患者依從性。
      • 老年人口越來越容易患糖尿病和相關併發症，因此需要有標靶治療。
    • 抑制因素
      • 雙胍類藥物的潛在副作用限制了患者的依從性
      • 雙胍類藥物的研究、開發和商業化高成本
    • 機會
      • 雙胍類藥物研發進展聚焦於新的遞送機制和製劑
      • 天然和植物來源雙胍藥物在食品和食品中越來越受歡迎
      • 不斷上漲的醫療保健成本和人們對文明病的認知不斷提高，正在新興市場創造商機
    • 任務
      • 新替代品對醫藥應用中雙胍類藥物需求的影響
      • 工業中長期使用雙胍類藥物所帶來的環境與健康問題
  • 市場區隔分析
    • 類型：Metformin因其有效性、安全性和經濟性而被廣泛使用。
    • 分銷管道：價格比較、定期藥品配送的訂閱服務以及購買自由增加了線上平台的參與度。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章雙胍類藥物市場：依類型

  • 芬福明
  • Metformin

第7章依藥物類別分類的雙胍類藥物市場

  • 品牌
  • 非專利的

第8章雙胍類藥物市場（按劑型）

  • 口服液
  • 藥片

第9章 處方雙胍類藥物市場

  • 緩釋性
  • 即時發布

第10章雙胍類藥物市場：按分銷管道分類

  • 離線
  • 線上

第11章 美洲雙胍類藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太雙胍類藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲雙胍類藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Zydus 的 Zitubimet XR 片劑獲得美國FDA核准
    • Lupin 收購勃林格殷格翰的兩個糖尿病品牌
    • Xigduo XR在中國核准用於治療成人第二型糖尿病
  • 戰略分析和建議

公司名單

  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Co Ltd.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Player Name
  • Sanofi SA
  • Servier Laboratories
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-3204321AF9EA

The Biguanides Market was valued at USD 5.24 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 5.37%, to USD 7.57 billion by 2030.

Biguanides, primarily used in the pharmaceutical sector, focus on compounds featuring the biguanide functional group, prominently Metformin, a leading treatment for type 2 diabetes. The scope of this market extends beyond diabetes care to potential applications in weight management and polycystic ovary syndrome (PCOS) treatments, showcasing its necessity across various therapeutic areas. The metabolic-improving properties of biguanides are driving their utility in end-use sectors such as pharmaceuticals and healthcare, alongside explorations in anti-aging therapies due to their potential longevity benefits. In terms of market insights, key growth influencers include the rising global incidence of diabetes and metabolic syndrome, spurring demand for biguanide-containing pharmaceuticals. Additionally, increasing investments in healthcare infrastructure and continuous innovations in drug development augment market trajectory. One notable opportunity rests in the expanding health-conscious demographic, prompting the need for safer, long-term diabetic management options, while another lies in the underexplored potential for biguanides in oncology as adjunct therapies. However, market growth encounters challenges such as the potential adverse effects of biguanides, like lactic acidosis, necessitating cautious administration and potential regulatory hurdles. Moreover, market saturation with generic versions presents competitive pricing pressure. Bets on innovation should focus on advancing formulation technologies to improve delivery mechanisms and reduce side effects, expanding the applicability of biguanides beyond conventional uses. Additionally, research into combination therapies could provide a competitive edge by offering enhanced therapeutic benefits. The market remains dynamic, driven by regulatory shifts and patent expiration timelines which influence competitive strategies. For sustained growth, companies should prioritize strategic partnerships and leverage data analytics to tailor patient-centric solutions that meet emerging needs. Keeping a keen eye on biotechnological advancements and healthcare reform can enhance adaptability and market penetration in this evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 5.24 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 7.57 billion
CAGR (%) 5.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biguanides Market

The Biguanides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
    • Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
    • Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
    • Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
  • Market Restraints
    • Potential side effects of Biguanides limiting patient adherence
    • High costs associated with research, development, and commercialization of Biguanides
  • Market Opportunities
    • Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
    • Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
    • Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
  • Market Challenges
    • The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
    • Environmental and health concerns associated with long-term use of biguanides in industries

Porter's Five Forces: A Strategic Tool for Navigating the Biguanides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biguanides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biguanides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biguanides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biguanides Market

A detailed market share analysis in the Biguanides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biguanides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biguanides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biguanides Market

A strategic analysis of the Biguanides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biguanides Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Co Ltd., Endo International PLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Player Name, Sanofi S.A., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Biguanides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Finformin and Metformin.
  • Based on Drug Class, market is studied across Branded and Generic.
  • Based on Dosage Form, market is studied across Oral Solutions and Tablets.
  • Based on Formulation, market is studied across Extended-release and Immediate-release.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of type 2 diabetes driving demand for effective treatment options like biguanides
      • 5.1.1.2. Rising healthcare expenditure and government initiatives boosting awareness and accessibility of diabetes medications
      • 5.1.1.3. Technological advancements in pharmaceutical formulations improving efficacy and patient compliance of biguanides
      • 5.1.1.4. Growing geriatric population more susceptible to diabetes and related comorbidities necessitating targeted treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential side effects of Biguanides limiting patient adherence
      • 5.1.2.2. High costs associated with research, development, and commercialization of Biguanides
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in biguanides research and development focused on novel delivery mechanisms and formulations
      • 5.1.3.2. Growing popularity of natural and plant-based biguanides in dietary supplements and nutraceuticals
      • 5.1.3.3. Opportunities in emerging markets with increasing healthcare spending and awareness of lifestyle diseases
    • 5.1.4. Challenges
      • 5.1.4.1. The effect of emerging alternatives on the demand for biguanides in pharmaceutical applications
      • 5.1.4.2. Environmental and health concerns associated with long-term use of biguanides in industries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide use of metformin owing to its efficacy, better safety profile, and affordability
    • 5.2.2. Distribution Channel: Increasing engagement on online platforms due to price comparison, subscription services for regular medication delivery, and purchasing discretion.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biguanides Market, by Type

  • 6.1. Introduction
  • 6.2. Finformin
  • 6.3. Metformin

7. Biguanides Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Branded
  • 7.3. Generic

8. Biguanides Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Oral Solutions
  • 8.3. Tablets

9. Biguanides Market, by Formulation

  • 9.1. Introduction
  • 9.2. Extended-release
  • 9.3. Immediate-release

10. Biguanides Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
  • 10.3. Online

11. Americas Biguanides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biguanides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biguanides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Zydus receives USFDA approval for Zituvimet XR tablets
    • 14.3.2. Lupin acquires two diabetes brands from Boehringer Ingelheim
    • 14.3.3. Xigduo XR approved in China for adults with type-2 diabetes
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals, Inc.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Bayer AG
  • 5. Biocon Limited
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Co Ltd.
  • 11. Endo International PLC
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Hikma Pharmaceuticals PLC
  • 15. Lupin Pharmaceuticals, Inc.
  • 16. Mallinckrodt Pharmaceuticals
  • 17. Merck & Co., Inc.
  • 18. Mylan N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Player Name
  • 22. Sanofi S.A.
  • 23. Servier Laboratories
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.
  • 26. Torrent Pharmaceuticals Ltd.
  • 27. Wockhardt Ltd.
  • 28. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. BIGUANIDES MARKET RESEARCH PROCESS
  • FIGURE 2. BIGUANIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIGUANIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIGUANIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIGUANIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIGUANIDES MARKET SIZE, BY FINFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIGUANIDES MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIGUANIDES MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIGUANIDES MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIGUANIDES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIGUANIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2023